^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CD19 (CD19 Molecule)

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    3d
    PLATYPS: Clinical Trial To Assess the Efficacy and Safety of PMCC-COE19 in Patients with CD19-Expressing B-Cell Malignancies (ACTRN12625001195448)
    P1, N=12, Recruiting, Peter MacCallum Cancer Centre | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    CD19 (CD19 Molecule)
    3d
    Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov)
    P1/2, N=27, Recruiting, Medical University of South Carolina | Trial completion date: Dec 2026 --> Sep 2027
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    cyclophosphamide • fludarabine IV • CD19-CD34t metabolically programmed CAR transduced T-cells
    5d
    in vivo CAR-T: A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=12, Recruiting, Therorna
    New P1 trial
    |
    CD19 (CD19 Molecule)
    5d
    Preclinical evidence of anti-CD19 CAR-T cell in vitro and in vivo efficacy against CD19-expressing acute myeloid leukemia. (PubMed, Curr Res Transl Med)
    These findings demonstrated CART19 efficacy against CD19+AML and allowed us to set up a clinical trial which is ongoing (NCT06649227), based on the injection of academically-produced CART19 in strictly selected patients with relapsed/refractory CD19+AML.
    Preclinical • Journal
    |
    CD19 (CD19 Molecule)
    6d
    A case of transient monoclonal plasma cell aberrancy following respiratory syncytial virus (RSV) vaccination. (PubMed, J Hematop)
    This case underscores the need for clinical awareness of post-vaccination immunologic phenomena that may mimic plasma cell neoplasm. Recognition of such transient aberrancies can prevent unnecessary invasive investigations and broaden understanding of vaccine-induced immune dynamics.
    Journal
    |
    CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule)
    9d
    Differential Expression of CD79B, CD19, and PD-L1 in de Novo and Transformed CD20-Negative Large B-Cell Lymphomas. (PubMed, Hematol Oncol)
    CD20-negative large B-cell lymphomas exhibit aggressive behavior and are ineligible for rituximab-containing therapy...In conclusion, CD79B and CD19 were variably expressed in CD20-negative large B-cell lymphomas, but lower in de novo DLBCL, and especially in plasmablastic lymphoma. Programmed cell death protein 1/programmed death-ligand one inhibitors may represent a treatment option.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • PD-1 (Programmed cell death 1) • CD79B (CD79b Molecule)
    |
    CD20 positive • CD20 negative
    |
    Rituxan (rituximab)
    11d
    Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells. (PubMed, Res Sq)
    CDNPs robustly expanded T cells from patients whose products could not be manufactured using standard approaches, and these CDNP-derived CAR T cells controlled tumors in humanized mouse models. In a phase I trial of patients with CD19⁺ malignancies (NCT04684563), cGMP-compatible CDNPs enabled streamlined 3-day manufacturing of IL-18-expressing CD19 CAR T cells, yielding higher cell recovery and durable clinical responses without unexpected toxicities, supporting CDNPs as a platform for commercial CAR T cell production.
    Journal
    |
    CD19 (CD19 Molecule) • IL18 (Interleukin 18) • IL15 (Interleukin 15) • IL7 (Interleukin 7) • CD86 (CD86 Molecule)
    12d
    A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=40, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    CD19 (CD19 Molecule)
    |
    clonoSEQ
    |
    Aucatzyl (obecabtagene autoleucel)
    13d
    A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders (clinicaltrials.gov)
    P1/2, N=58, Completed, National Research Center for Hematology, Russia | Recruiting --> Completed | Trial completion date: Mar 2026 --> Nov 2025
    Trial completion • Trial completion date • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    TP53 mutation
    17d
    A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma. (PubMed, bioRxiv)
    Yang et al. describe X-LYMPH ( X enografts of Lymph oma), a publicly available and molecularly annotated PDX repository that captures the heterogeneity of large B-cell lymphoma. X-LYMPH includes models of chimeric antigen receptor T cell resistance, providing a shared foundation for mechanistic research and therapeutic development for lymphomas.
    Journal
    |
    CD19 (CD19 Molecule)
    17d
    A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases (clinicaltrials.gov)
    P1, N=30, Recruiting, Grit Biotechnology
    New P1 trial
    |
    CD19 (CD19 Molecule)
    17d
    Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1/2, N=66, Recruiting, National Cancer Institute (NCI) | N=132 --> 66
    Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV